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ABSTRACT 
Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality in the United 
States. Over 50% of patients with CRC will develop local recurrence or distant organ metastasis. 
Cancer stem cells play a major role in the survival and metastasis of cancer cells. In this study, 
we examined the effects of novel AMP-activated protein kinase (AMPK) activating compounds 
on CRC metastatic and stem cell lines as potential candidates for chemotherapy. We found that 
activation of AMPK by all fluorinated N,N-diarylureas (FND) compounds at micromolar levels 
significantly inhibited the cell cycle progression and subsequent cellular proliferation. 
Additionally, we demonstrated that select FNDs significantly increased apoptosis in CRC 
metastatic and cancer stem cells. Therefore, FNDs hold considerable promise in the treatment of 
metastatic CRC, through elimination of both regular cancer cells and cancer stem cells. 
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INTRODUCTION 
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States 
(1). This high mortality rate is largely attributed to tumor metastasis and recurrence (2). At initial 
presentation, more than half of all patients display metastatic disease in regional lymph nodes or 
systemic organs (e.g., liver). The five-year survival rate for patients with metastatic CRC is 
approximately 13%, as compared to 90% for non-metastatic disease (1). A growing body of 
evidence suggests that cancer stem cells play a role in the resistance and spread of cancer cells 
(2-4). Cancer stem cells are a subpopulation of tumor cells that are capable of self-renewal and 
display resistance to DNA damage-induced cell death, a ruinous property that allows metastatic 
tumors to survive initial treatments and re-populate. Developing new anti-neoplastic agents that 
selectively target cancer stem cells represents a potentially valuable treatment to improve CRC 
outcomes (2-4).  
Cancer stem cells possess demanding metabolic requirements and survival mechanisms 
that are potential targets for treatment (5). One such critical pathway involves AMP-activated 
protein kinase (AMPK), which coordinates growth, autophagy, and metabolism (6). AMPK acts 
as a metabolic sensor for the ratio of AMP to ATP in cells and has several downstream 
transcriptional targets (6). Among the anti-neoplastic effects of AMPK activation are cell cycle 
arrest through stabilization of p53 and cyclin-dependent kinase inhibitors p21waf1 and p27kip1, 
inhibition of macromolecular synthesis, inhibition of mTORC1, and inhibition of the Warburg 
effect (7, 8). In support of the particular importance of AMPK in cancer cells and cancer stem 
cells, the widely studied AMPK activator, metformin, reduces cancer incidence in diabetic 
populations for many different cancers, including CRC (9). Furthermore, in vitro and in vivo 
studies with metformin specifically show cytotoxicity toward cancer stem cells (10, 11).  
on June 6, 2019. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2017; DOI: 10.1158/1535-7163.MCT-15-0634 
5 
 
We identified the anti-neoplastic effects of fluorinated N,N’-diarylureas (FNDs) in a 
high-throughput screening program (12) and found that several potent FNDs inhibited growth of 
CRC cell lines through inhibition of the mTOR pathway (12). Overexpression of mTORC1 and 
mTORC2 components, Raptor and Rictor, is important to tumorigenesis (13), and the activation 
of AMPK regulates cell growth by suppressing mTORC1 through direct phosphorylation of the 
tumor suppressor, TSC2, and Raptor (6). Through this mechanism, we anticipated that AMPK 
activation would directly inhibit CRC cell proliferation.  
In this study, we investigated the ability of eight FNDs to inhibit growth and induce 
apoptosis in CRC metastatic cell lines and stem cells. Activation of AMPK by all FND 
compounds successfully inhibited cell cycle progression and subsequent cellular proliferation. 
These results demonstrate that FNDs exhibit considerable promise in the treatment of metastatic 
CRC, predominantly through the inhibition of CRC stem cells.  
 
MATERIALS AND METHODS 
FNDs. FNDs were synthesized as previously described (12). Table 1 shows the FNDs 
used in this study. Stock solutions (10 mM) in dimethyl sulfoxide (DMSO) were stored at -20°C.  
Cell lines and culture maintenance. Human cell line HT29 was purchased from 
American Type Culture Collection. KM20 was provided by Dr. Isaiah J. Fidler (M.D. Anderson 
Cancer Center, Houston, TX); STR validation analysis (Bio-Synthesis, Lewisville, TX) yielded a 
full DNA profile and no contamination by another human cell line was detected; there were no 
matches after searching ATCC, JCRB or DSMZ databases. HCT116 pik3ca wild-type and 
mutant cell lines were a gift from Dr. J. Wang (14). Human CRC stem cell line 1 (#36112-39; lot 
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#12121800-05) and stem cell line 2 (#36112-39; lot #1313161-12) were purchased from 
Celprogen (Torrance, CA). Cancer stem cells were limited to less than 12 passages.  
Cell lines were routinely grown as monolayer cell cultures in 5% CO2 in air, and 100% 
relative humidity at 37°C. HT29 and KM20 cell lines were grown in McCoy’s 5A medium 
(Sigma-Aldrich, St. Louis, MO) and supplemented with 10% FBS and 1X antibiotic-antimycotic 
(Life Technologies, Carlsbad, CA). Stem cell lines were grown in Cancer Stem Cell Complete 
Growth Media with Serum without antibiotic on pre-coated flasks with Human Colon Cancer 
Stem Cell Extra-cellular Matrix (both from Celprogen). Cell passages were carried out by 
detaching adherent cells in a logarithmic growth phase by addition of a mixture of 0.25% trypsin 
with 0.02% EDTA (Sigma Aldrich) and incubating for 10-15 min at 37°C. The number of viable 
cells was estimated with a cell counter V-CELL XR (Beckman Coulter, Miami, FL). Metformin 
HCl was purchased from Seleckchem (Pittsburgh, PA). 
Cytotoxicity SRB assay. For each experiment, cell lines were seeded in two 96-well 
plates in normal medium (5x103 cells/well, 100 µL). At 24 h, 100 µL of media with drugs at 
different concentrations were added to each well. DMSO was used as a treatment control. Cell 
viability was measured using the Cytoscan-SRB Cell Cytotoxicity Assay (G-Biosciences, St. 
Louis, MO) according to manufacturer’s instructions. Cell viability was plotted as a percentage 
relative to DMSO treatment alone. IC50 values were approximated by plotting viability over a 
range of concentrations.  
Western blot analysis and antibodies. Total protein lysates were resolved on a 4-12% 
bis-tris gel and transferred to Immobilon PVDF transfer membranes. Membranes were incubated 
for 1 h at room temperature in blocking solution (TRIS-buffered saline containing 10% nonfat 
dried milk and 0.1% Tween 20), followed by an overnight incubation in primary antibodies at 
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4°C. Membranes were washed 3 times and incubated with horseradish peroxidase-conjugated 
secondary antibodies for 1 h. After 3 additional washes, the immune complexes on the 
membranes were visualized using Immobilon Western Chemiluminescent HRP substrate (EMD 
Millipore, Billerica, MA) or Amersham ECL (GE Life Sciences, Pittsburg, PA).  
Antibodies for western blot analysis included the following: PARP (#9542, 1:1000), 
Phospho-AMPKα (#2531, Thr172, 1:1000), Phospho-S6 Ribosomal Protein (Ser235/236) (Cell 
Signaling, Danvers, MA); Cyclin D1 (Abcam, Cambridge, MA; #AB34175, 1:5000); β-actin 
(Sigma Aldrich, #A5441, 1:20000); anti-rabbit and anti-mouse (Santa Cruz Biotechnology, #SC-
2054, #SC-2055, 1:3000).  
Patient tumor engraftment into SCID mice and PDX cell line establishment. The 
original patient CRC tumor (F0 generation) was divided and implanted into the flanks of NOD 
scid gamma mice (The Jackson Laboratory; 005557). When the resulting tumors (F1 generation) 
grew to 1 cm3, they were resected, divided into 2-mm3 pieces, and implanted into 5 mice (F2 
generation). All animal studies were performed in accordance with policies of the Institutional 
Animal Care and Use Committee and were approved by the Institutional Review Board of the 
University of Kentucky. 
Liberase DH Research Grade (05401054001; Roche Applied Science) was resuspended 
in sterile water at a 2.5 mg/ml concentration and stored in single-use 100 µl aliquots at -80°C. 
Collagenase/Hyaluronidase (07912; StemCell Technologies) was aliquoted into single-use 250 
µl aliquots and stored at -80°C. Upon collection, PDX tumors (F2 generation) were placed into 
DMEM complete cell culture media supplemented with 1X Gibco Antibiotic-Antimycotic 
(15240-062; Life Technologies) for transportation. Tumor fragments were minced into 2-mm 
cubes using scissors and digested in 50 µg/ml Liberase DH (100 µl) and 0.5X 
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Collagenase/Hyaluronidase (250 µl), diluted in 5 mL of DMEM serum free media for 4 h at 
37°C with gentle agitation by magnetic stirring bar. No undigested tissue was observed; cells 
were washed twice with complete cell culture media and transferred into 10% FBS DMEM 
media supplemented with 1X Gibco Antibiotic-Antimycotic. 
Statistical analysis. Analysis of variance was employed for comparison of cell viability 
across DMSO and varying dose levels of FND treatment, and adjusted p-values using the Holm’s 
procedure were calculated for pairwise comparison of each dose level with DMSO.  
 
RESULTS 
Treatment with FNDs induces cell cycle inhibition and apoptosis in metastatic CRC 
cells. We performed a high-throughput screen of N,N’-diarylureas to identify potent AMPK 
activators and selected eight active agents (Table 1)(12). Next, HT29 cells were treated with the 
8 agents (FND 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h) for 48h. Decreased cell viability was evident at a 
drug dose as low as 5 µM, and was below 50% for all 8 compounds treated at the 25 µM dose 
(Table 2). To determine whether the prominent decrease in cell viability was due to cell cycle 
inhibition or apoptosis induction, KM20 and HT29 CRC cells were treated with each of the 8 
FNDs for 24h at 25 μM or 50 μM. Cyclin D1 expression and PARP cleavage were analyzed by 
western blot. Cyclin D1 expression was drastically decreased in both cell lines after treatment 
with FND 4b, 4c, 4d, 4e, 4f, 4g, and 4h at 25 µM (Fig. 1A). Prominent PARP cleavage was 
observed after treatment at the 50 µM dose, notably after treatment with the 4b compound (Fig. 
1B).  
Treatment with FNDs induces cell cycle inhibition and apoptosis in cancer stem cells. 
CRC stem cell lines were treated with FND 4b, 4d, 4f, 4g and 4h at 50 μM for 24h and analyzed 
for cyclin D1 expression and PARP cleavage. Cyclin D1 expression was decreased in all 
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treatment groups; prominent PARP cleavage was observed in both stem cell lines only after 
treatment with FND 4b (Fig. 2A). Activation of apoptosis is especially important for elimination 
of cancer stem cells, since these cells are progenitors for tumor progression; FND 4b treatment 
induced apoptosis in both metastatic cancer cells and cancer stem cells. To confirm that AMPK 
activation was dose responsive in CRC stem cells, we treated CRC stem cell line 1 with 5, 25 
and 50 µM of FND 4b. Our results showed a dose-dependent AMPK activation after FND 4b 
treatment (Fig. 2B). 
Next, we used compound 4b to evaluate dose-dependent AMPK activation in KM20 and 
HT29 cells. We observed AMPK activation starting with as little as 10 µM (Fig. 3A). We also 
examined the dose dependent effects of FND 4b treatment on cell viability (Fig. 3B), cell cycle, 
and apoptosis induction in KM20 and HT29 cells. KM20 cells were more sensitive to compound 
4b treatment and showed marked suppression of cyclin D1 expression at a dose of 10 µM. PARP 
cleavage was detected in both cell lines starting at a 40 µM dose.  
Treatment with FND 4b induces cell cycle inhibition and apoptosis in pik3ca mutant 
colorectal cancer cells. We evaluated whether the pik3ca mutation protects cancer cells against 
FND 4b treatment. HCT116 pik3ca mutant and wild-type CRC cell lines were treated with FND 
4b at 10, 20, 30, 40 and 50 μM for 24h. Both cell lines showed strong cell cycle inhibition but 
required higher dosages compared to KM20 and HT29 cell lines. PARP cleavage was noted with 
FND 4b treatment at 20 µM (Fig. 4A). These results show that the HCT116 pik3ca mutant and 
wild-type cells have a similar pattern of cell cycle inhibition and apoptosis in response to FND 
4b treatment.  
Metformin, which is a known activator of AMPK and is used for diabetes treatment and 
cancer prevention, activates AMPK at millimolar levels (15). AMPK downregulates TOR/S6K 
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activity via TSC2 in response to stress (16). We treated HT29 and KM20 cells with FND 4b at 
10, 20, 30 μM and with metformin at 5, 10 and 20 mM for 24h to compare the effect on cyclin 
D1 expression and S6 phosphorylation at Ser234/235. Both metformin and FND 4b decreased 
phosphorylation of the S6 protein, a downstream effector of mTOR that is a crucial signaling 
pathway for proliferation and survival of cancer cells in vitro as well as tumors in vivo (Fig. 4B, 
C). Our results demonstrated that FND 4b had a similar effect on cell cycle inhibition and 
inhibition of S6 phosphorylation at the 20 µM dose as compared to the 10 mM dose of 
metformin.  
Treatment of CRC cells, stem cells and PDX cell line with low dose FND 4b. To 
determine the effect of FND treatment on AMPKα activation, HT29 cells were treated with low 
dosages (i.e., 5 and 10 μM) of FND 4b for 12, 24, 48 and 72h. FND treatment demonstrated a 
long-lasting effect on AMPK activation at 10 μM (Fig. 5A). Low-dose FND 4b treatment 
resulted in a strong AMPKα activation, and decreased cyclin D1 expression in CRC stem cells at 
48h (Fig. 5B, C). Next, we established a cell line from a patient-derived xenograft (PDX) and 
treated it with low-dose FND 4b for 48h. Cyclin D1 expression was markedly suppressed in the 
PDX cell line (Fig. 5D). FND treatment at 5, 7.5 and 10 µM significantly decreased stem cells 
and PDXL proliferation (Fig. 5 B, C, D; lower panels). Low-dose FND treatment did not 
increase PARP cleavage in all tested cells (data not shown). These results demonstrate a long-
lasting effect of low-dose FND 4b treatment on AMPKα activation and cell cycle inhibition. 
 
DISCUSSION 
The central regulatory role played by AMPK in energy homeostasis makes it an attractive 
target for treatment of various diseases such as diabetes and cancer (6, 7, 17). Recent efforts have 
focused on elucidating the complex role of AMPK in cancer cell viability (18). We examined the 
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effects of 8 fluorinated N,N’-diarylureas as AMPK activators on CRC metastatic and stem cell 
lines to evaluate their potential utility as chemotherapeutic agents for CRC. The FNDs that were 
used in this study represent a new class of AMPK activators with no effect on AKT or ERK, 
unlike other N,N’ diarylureas [12]. We confirmed that FND treatment of CRC metastatic and 
stem cell lines resulted in dose-dependent AMPK activation. High doses of traditional AMPK 
activators, such as AICAR and metformin, were required to achieve anti-cancer effects (10-12, 
19). However, similar to FNDs, more recent AMPK activators showed anti-tumorigenic effects 
at lower concentrations. Chen et al. (19) showed that plumbagin, an AMPK activator, induced 
apoptosis and inhibited growth of CRC cell lines at a treatment concentration of 10 µM. Kaushik 
et al. (20) showed that honokiol, another AMPK activating compound, inhibited melanoma 
growth and spheroid-forming capacity (i.e., stemness) through AMPK activation at 
concentrations up to 50 µM. Finally, Valtorta et al. (21) showed that 1-4 diaryl-azetidinone, also 
a novel AMPK activator, inhibited human CRC xenografts in mouse models at IC50 in the nM to 
1 µM range. Taken together, these studies suggested that targeting cancer cells with novel 
AMPK activators represent an effective strategy for the treatment of different types of cancers. 
Thus, the beneficial effects on metastatic cancer cells by AMPK activation provide a rationale 
for further studies, to determine the potential clinical utility of AMPK activators, like FNDs, on 
cancer stem cells.  
In our study, we evaluated the effect of FNDs on CRC stem cells. Many cancer stem cell 
models have been described, but a unifying theme in tumorigenesis is that tumors are not 
homogeneous. A hierarchical structure within tumors includes a small subset of cells with long-
term self-renewal and differentiation capacity (3). CRC, in particular, is known to possess cancer 
stem cells (22). In order to survive, re-populate, and differentiate, cancer stem cells have 
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developed several mechanisms that provide resistance to the effects of anti-neoplastic agents. 
These mechanisms include resistance to DNA damage, drug penetration, apoptosis, and reactive 
oxygen species (ROS) (3-5). Up-regulation of the DNA repair machinery and down-regulation of 
telomerase allow cancer stem cells to maintain their genetic integrity. Cancer stem cells also up-
regulate efflux transporters from the ATP-binding cassette (ABC) gene family to efficiently 
extrude chemotherapy agents. Resistance to apoptosis occurs, in part, through Akt pathway 
activation and increased production of apoptosis inhibitor proteins. Finally, cancer stem cells 
increase their free radical scavenging machinery to protect themselves from ROS damage (4). 
Several studies have investigated the role of stem cells in treatment resistance (2, 11). For 
example, Zhou et al. [2] created cisplatin-resistant CRC cells and found that these cells had stem 
cell-like markers. Treatment with salinomycin caused an accumulation of ROS and down-
regulation of anti-apoptotic molecules, which suggested that salinomycin was able to overcome 
the cisplatin resistance of CRC cells. Since cancer stem cells possess these survival mechanisms, 
cancer treatment plans should include therapy to specifically target cancer stem cells in order to 
reduce future recurrence and metastasis.  
While the specific role of AMPK in cancer stem cells compared with the non-stem cell 
population has not yet been fully characterized, several studies have shown that metformin, an 
AMPK activator, is preferentially cytotoxic to cancer stem cells in pancreatic and breast cancers 
(10, 11, 23). Similarly, in our present study, we showed that FND treatment resulted in cell cycle 
arrest in CRC stem cells. AMPK activation led to inhibition of macromolecular synthesis, 
inhibition of mTORC1, and onset of the ‘anti-Warburg effect’ (7, 24, 25), all of which led to the 
inhibition of cancer cell proliferation. Hardie and Alessi (7) described several AMPK tumor 
suppressor functions that included cell cycle arrest through stabilization of p53, p21 and p27. 
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Particularly in cancer stem cells, it is likely that the anti-Warburg effect targets the utilization of 
anaerobic glycolysis by cancer stem cells, and decreases their ability to use AKT-mTOR. AMPK 
activation of apoptosis resulted from p53 phosphorylation; phosphorylated AMPK subsequently 
accumulated in the mitochondria and interacted with Bak to induce apoptosis (8). Our results 
demonstrated that AMPK activation reduced the ability of cancer stem cells to hijack energy 
metabolism for growth and proliferation and triggered an apoptotic cascade. In summary, we 
demonstrated that FNDs activated AMPK at micromolar concentrations, which resulted in 
consistent cell cycle arrest and apoptosis in all cancer cell lines that were studied. These findings 
provide additional information regarding the role of AMPK activation in cancer stem cells and 
demonstrate a potential role of FNDs in the treatment of metastatic CRC.  
 
 
ACKNOWLEDGEMENTS 
The authors thank the Markey Cancer Center’s Research Communications Office for help 
with manuscript preparation, and the Biostatistics and Bioinformatics Shared Resource Facility 
for statistical analysis. The contents of this manuscript are solely the responsibility of the authors 
and do not necessarily represent the official views of the grant funding agencies.  
  
on June 6, 2019. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2017; DOI: 10.1158/1535-7163.MCT-15-0634 
14 
 
REFERENCES  
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. 
2. Zhou J, Li P, Xue X, He S, Kuang Y, Zhao H, et al. Salinomycin induces apoptosis in 
cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species. 
Toxicol Lett 2013;222:139-45. 
3. Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 
2013;13:727-38. 
4. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, et al. Targeting the 
mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell 
hypothesis. J Oncol 2011;2011:941876. 
5. Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. 
Nat Rev Mol Cell Biol 2014;15:243-56. 
6. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, 
autophagy and metabolism. Nat Cell Biol 2011;13:1016-23. 
7. Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolism link - ten years 
after. BMC Biol 2013;11:36. 
8. Nieminen AI, Eskelinen VM, Haikala HM, Tervonen TA, Yan Y, Partanen JI, et al. Myc-
induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. 
Proc Natl Acad Sci U S A 2013;110:E1839-48. 
9. Sehdev A, Shih YC, Vekhter B, Bissonnette MB, Olopade OI, Polite BN. Metformin for 
primary colorectal cancer prevention in patients with diabetes: a case-control study in a 
US population. Cancer 2015;121:1071-8. 
on June 6, 2019. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2017; DOI: 10.1158/1535-7163.MCT-15-0634 
15 
 
10. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer 
stem cells, and acts together with chemotherapy to block tumor growth and prolong 
remission. Cancer Res 2009;69:7507-11. 
11. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, et al. Metformin kills and 
radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2012;2:362. 
12. Sviripa V, Zhang W, Conroy MD, Schmidt ES, Liu AX, Truong J, et al. Fluorinated 
N,N'-diarylureas as AMPK activators. Bioorg Med Chem Lett 2013;23:1600-3. 
13. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al. mTORC1 and 
mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 
signaling pathways. Cancer Res 2011;71:3246-56. 
14. Guo XN, Rajput A, Rose R, Hauser J, Beko A, Kuropatwinski K, et al. Mutant PIK3CA-
bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer 
Res 2007;67:5851-8. 
15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated 
protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74. 
16. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth 
and survival. Cell 2003;115:577-90. 
17. Fay JR, Steele V, Crowell JA. Energy homeostasis and cancer prevention: the AMP-
activated protein kinase. Cancer Prev Res (Phila) 2009;2:301-9. 
18. Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Res 
2013;73:2929-35. 
on June 6, 2019. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2017; DOI: 10.1158/1535-7163.MCT-15-0634 
16 
 
19. Chen MB, Zhang Y, Wei MX, Shen W, Wu XY, Yao C, et al. Activation of AMP-
activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth 
inhibition in cultured human colon cancer cells. Cell Signal 2013;25:1993-2002. 
20. Kaushik G, Kwatra D, Subramaniam D, Jensen RA, Anant S, Mammen JM. Honokiol 
affects melanoma cell growth by targeting the AMP-activated protein kinase signaling 
pathway. Am J Surg 2014;208:995-1002; discussion 1-2. 
21. Valtorta S, Nicolini G, Tripodi F, Meregalli C, Cavaletti G, Avezza F, et al. A novel 
AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse 
xenograft model of colorectal cancer. Invest New Drugs 2014;32:1123-33. 
22. Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A, et al. Cancer stem cells 
in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World 
J Gastroenterol 2014;20:923-42. 
23. Fasih A, Elbaz HA, Huttemann M, Konski AA, Zielske SP. Radiosensitization of 
pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res 
2014;182:50-9. 
24. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al. AMPK is a negative 
regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 
2013;17:113-24. 
25. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control 
in tumour suppression. Nat Rev Cancer 2009;9:563-75. 
 
  
on June 6, 2019. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2017; DOI: 10.1158/1535-7163.MCT-15-0634 
17 
 
Table 1. Fluorinated N,N’-diarylureas (FNDs) with substituents X or Y in the “first” aryl ring 
and substituents A,B,C,D in the “second aryl” ring. AMPK activation ratios were relative to 
compound 3 from a previous study [13]. 
 
Compound Structure Formula MW 
AMPK 
Activation 
Ratio
X Y A B C D 
4a  C15H10F6N2O2 364.243 2.37 CF3O H   CF3  
4b  C15H9ClF6N2O2S 430.753 2.60 CF3O H  Cl SCF3  
4c  C15H10F6N2OS 380.308 2.16 H CF3S   CF3  
4d  C14H9Cl2F3N2OS 381.200 1.94 H CF3S  Cl  Cl 
4e 
 
C14H8F6N2O 334.217 4.00 CF3 H  F F F 
4f 
 
C14H8F6N2OS 366.282 2.02 CF3S H  F F F 
4g 
 
C14H8Cl3F3N2OS 415.645 2.32 CF3S H  Cl Cl Cl 
4h 
 
C14H7F7N2OS 384.272 2.48 CF3S H F F F F 
 
 
  
on June 6, 2019. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2017; DOI: 10.1158/1535-7163.MCT-15-0634 
18 
 
Table 2. Effect of FNDs on metastatic CRC cell viability. HT29 cells were seeded in 96-well 
plates in complete medium (5x103/well) and treated with 8 different FNDs (4a-4h). DMSO (25 
μM) was used as a treatment control. Cell viability was measured using an SRB assay after 48h 
of FND exposure and plotted as a percentage relative to DMSO treatment alone. Each 
measurement was performed in sextuplicate; *p≤0.05. 
 
Compound Control 5 µM  10 µM 25 µM 
4a 100 67.7* 23.1* 15.5* 
4b 100 36.0* 22.2* 8.3* 
4c 100 21.4* 21.0* 6.6* 
4d 100 24.1* 19.3* 4.8* 
4e 100 29.9* 23.6* 9.7* 
4f 100 20.9* 21.0* 5.1* 
4g 100 22.6* 23.2* 7.5* 
4h 100 23.2* 20.0* 6.3* 
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Figure Legends 
 
Figure 1. Effect of FNDs on cyclin D1 expression and PARP cleavage in metastatic CRC 
cell lines. A, B. KM20 and HT29 CRC cells were seeded in 6-well plates (8x105/well) in 
complete medium and treated 24h later with 8 different FNDs (4a-4h) for 24h at 25 μM (A) and 
50 μM (B). Cyclin D1 expression and PARP cleavage (PARP cleaved product 85 kDa; arrow) 
was assessed by western blot analysis; β-actin was used as a loading control.  
 
Figure 2. Effect of FNDs on PARP cleavage and cyclin D1 and pAMPK expression in CRC 
stem cell lines. A. CRC stem cell line 1 and stem cell line 2 were seeded in 6-well plates in 
complete medium and treated 24h later with FNDs 4b, 4d, 4f, 4g and 4h at 50 μM for 24h. 
Cyclin D1 expression and PARP cleavage (PARP cleaved product 85 kDa; arrow) was analyzed 
by western blot. DMSO (50 μM) was used as a treatment control, and β-actin was used as a 
loading control. B. CRC stem cell line 1 was seeded in 6-well plates (8x105/well) in complete 
medium and treated 24h later with FND 4b at 5, 25 and 50 μM for 12h. AMPKα phosphorylation 
(Thr172) was analyzed by western blot. DMSO (50 μM) was used as a treatment control, and β-
actin was used as a loading control. Densitometry was performed with ImageJ software; relative 
pAMPKα (Thr172) band intensity was normalized to β-actin and quantified with respect to 
control set at 1.0.  
 
Figure 3. Treatment of CRC cell lines with FND 4b. A. KM20 and HT29 CRC cells were 
seeded in 6-well plates (8x105/well) in complete medium and treated 24h later with FND 4b at 
10, 20, 30, 40 and 50 μM for 12h. AMPKα phosphorylation (Thr172) was assessed by western 
blot analysis. DMSO (50 μM) was used as a treatment control, and β-actin was used as a loading 
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control. Densitometry was performed with ImageJ software; relative pAMPKα (Thr172) band 
intensity was normalized to β-actin and quantified with respect to control set at 1.0. B. KM20 
and HT29 CRC cells were seeded in 6-well plates (8x105/well) in complete medium for 24h and 
treated with FND 4b at 10, 20, 30, 40 and 50 μM for 24h. Cyclin D1 expression and PARP 
cleavage (cleaved product 85 kDa; arrow) was assessed by western blot analysis. DMSO (50 
μM) was used as a treatment control, and β-actin was used as a loading control.  
 
Figure 4. Treatment of Pik3ca mutant CRC cells with FND 4b. A. HCT116 pik3ca wild-type 
and pik3ca mutant cell lines were seeded in 6-well plates (8x105/well) in complete medium for 
24h and treated with FND 4b at 10, 20, 30, 40 and 50 μM for 24h. Cyclin D1 expression and 
PARP cleavage (PARP cleaved product 85 kDa; arrow) was analyzed by western blot. DMSO 
(50 μM) was used as a treatment control; β-actin was used as a loading control. B. C. HT29 and 
KM20, respectively, cells were seeded in 24-well plates (5x105/well) in complete medium and 
treated 24h later with 5, 10, 20 mM metformin and FND 4b at 10, 20, 30 μM for 24h. Cyclin D1 
(arrow), S6 phosphorylation (Ser234/235) and total S6 expression was analyzed by western blot. 
DMSO (30 μM) was used as a treatment control; β-actin was used as a loading control. 
 
Figure 5. Low dose FND 4b treatment. A. HT29 CRC cells were seeded in 6-well plates 
(8x105/well) in complete medium for 24h and treated with FND 4b at 5 and 10 μM for 12, 24, 48 
and 72h. AMPKα phosphorylation (Thr172) was analyzed by western blot. DMSO (10 μM) was 
used as a treatment control; β-actin was used as a loading control. B, C. (Upper panels) CRC 
stem cell line 1 and stem cell line 2 were seeded in 6-well plates in complete medium and treated 
24h later with 5 μM FND 4b for 48h. AMPKα phosphorylation (Thr172) and cyclin D1 
expression were analyzed by western blot. DMSO (10 μM) was used as a treatment control; β-
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actin was used as a loading control. (Lower panels) Stem cells were seeded in 96-well plates in 
complete medium (5x103/well) and treated with FND 4b. Cell viability (lower panels) was 
measured using an SRB assay after 48h of FND exposure and plotted as a percentage relative to 
DMSO treatment alone. Graphic representations are the mean ± SE; each measurement was 
performed in sextuplicate. D. PDX cell line was seeded in 6-well plates (8x105/well) in complete 
medium and treated 24h later with FND 4b at 5 and 10 μM for 48h. Cyclin D1 expression was 
analyzed by western blot (upper panel). DMSO (10 μM) was used as a treatment control; β-actin 
was used as a loading control. PDX cell line was seeded in 96-well plates in complete medium 
(5x103/well) and treated with FND 4b. Cell viability (lower panel) was measured using an SRB 
assay after 48h of FND exposure and plotted as a percentage relative to DMSO treatment alone. 
Graphic representations are the mean ± SE; each measurement was performed in sextuplicate; 
*p≤0.05. 
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